medigraphic.com
Boletín Médico del Hospital Infantil de México

2005, Number 5

<< Back Next >>

Bol Med Hosp Infant Mex 2005; 62 (5)

Mexican Society for Pediatric Endocrinology’s recommendations for the use of human biosynthetic growth hormone in children and adolescents.

Calzada-León R, Dorantes-Álvarez LM, Barrientos-Pérez M

Language: Spanish
References: 72
Page: 362-374
PDF size: 118.57 Kb.


ABSTRACT

The aim of this paper is to present consensus guidelines for the diagnosis and treatment of children and adolescents with growth hormone deficiency, and to alert on several crucial points regarding the use of human biosynthetic growth hormone: a) the mechanism of action of natural human growth hormone; b) how to establish clinical suspicious of growth hormone deficiency; c) utility of different biochemical studies to confirm growth hormone deficiency; d) physical and chemical characteristics of the commercial kits of growth hormone; e) how to prepare and use the growth hormone kits to ensure their efficacy; f) general objectives of growth hormone treatment; g) formal indications for the use of human growth hormone; h) define dose, time and periodicity during treatment; i) efficacy parameters of growth hormone treatment; j) factors that modify the efficacy of growth hormone treatment; k) safety parameters during growth hormone treatment; l) when, how and in who stop the treatment with growth hormone.


REFERENCES

  1. Participants of the Scientific Weekend, Human Growth Hormone, Viena 10-11th October, 2003. Childhood growth hormone deficiency and idiopathic short stature: How far can a Consensus go? J Pediatr Endocrinol Metab. 2004; 17: 251-6.

  2. Werther GA, Wang M, Cowell CT. An auxology-based growth hormone program: update of the Australian experience. J Pediatr Endocrinol Metab. 2003; 16 Supl 3: 613-8.

  3. Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society: Guidelines for the use of growth hormone in children with short stature. A report by the Drug and Therapeutics Committee of the Lawson Wilkins Pediatric Endocrine Society. J Pediatr. 1995; 127: 857-67.

  4. American Academy of Pediatrics. Considerations related to the use of recombinant human growth hormone in children. Pediatrics. 1997; 99: 122-9.

  5. Kappelgaard AM, Bojesen A, Skydsgaard K, Sjogren I, Laursen T. Liquid growth hormone: preservatives and buffers. Horm Res. 2004; 62 Supl 3: 1-6.

  6. Jacobsen L, Rolan P, Christensen M. Bioequivalence between ready-to-use human recombinant growth hormone (rhGH) and GH for reconstitution. Growth Horm IGF Res. 2000; 10: 93-8.

  7. Ryan B, Selby R, Gingell R. Two generation reproduction study and immunotoxicity screen in rats dosed with phenol via the drinking water. Int J Toxicol. 2001; 20: 121-42.

  8. Svendsen O, Cartensen J. Antimicrobial excipients and local damage at injection sites. J Vet Pharmacol Ther. 1997; 20 Supl 1: 252-93.

  9. Main K, Jorgensen J, Hertel N. Automatic needle insertion diminishes pain during growth hormone injection. Acta Paediatr. 1995; 84: 331-4.

  10. Jorgensen JT. Improvement of patient convenience in treatment with growth hormone. J Pediatr Endocrinol. 1994; 7: 175-80.

  11. Bojesen A, Hansen B, Laursen T. Perception of pain after injection of subcutaneous growth hormone in healthy volunteers. Horm Res. 2002; 58 Supl 2: 106.

  12. Hansen B, Bojesen A, Laursen T. The perception of pain after subcutaneous injection of 5 different medias containing different solutions for use in the dissolution human growth hormone in healthy volunteers. Horm Res. 2002; 58 Supl 2: 106.

  13. Laursen T, Bojesen A. Pain perception after injection of different excipients used in growth hormone formulations. Growth Horm IGF Res. 2002; 12 Supl: 234.

  14. Hansen B. Assessment of pain experience by injection of solvents implying different buffers in healthy adult subjects. Growth Horm IGF Res. 2000; 10 Supl: 167.

  15. Bojensen A, Hansen B, Laursen T. Perception of pain after subcutaneous injection of solutions with different protein concentrations. Growth Horm IGF Res. 2002; 12 Supl: 234.

  16. Smith S, Hindrmarch P, Brook C. Compliance with growth hormone treatment. Arch Dis Child. 1993; 68: 91-3.

  17. Shalet SM, Toogood A, Rahim A, Brennan BMD. The diagnosis of growth hormone deficiency in children and adults. Endocr Rev. 1998; 19: 203-23.

  18. Saggese G, Ranke MB, Saenger P, Rosenfeld RG, Tanaka T, Chaussain JL, et al. Diagnosis and treatment of growth hormone deficiency in children and adolescents; towards a consensus. Horm Res. 1998; 50: 320-40.

  19. Gluckman PD. Growth hormone deficiency diagnosed and treated during the first 2 years of live: evidence for the role of growth hormone in human perinatal growth. En: Ranke MB, Gunnarsson R, editores. Progress in growth hormone therapy – 5 years of KIGS. Manhnheim: J & J Verlag; 1994. p. 88-96.

  20. Growth Hormone Research Society (GRS). Consensus guidelines for the diagnosis and treatment of adult with GH deficiency. Statement of the GRS workshop on adult growth hormone deficiency. J Clin Endocrinol Metab. 1998; 83: 379-81.

  21. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of growth hormone deficiency in childhood and adolescence: Summary statement of the Growth Hormone Research Society. J Clin Endocrinol Metab. 2000; 85: 3990-3.

  22. Growth Hormone Research Society. Critical evaluation of the safety of recombinant human growth hormone administration: Statement from the Growth Hormone Research Society. J Clin Endocrinol Metab. 2001; 86: 1868-70.

  23. Ranke MB, Lindberg A, Chatelain P, Wilton P, Cutfield W, Albertsson-Wikland K, et al, on behalf of the KIGS International Board. Kabi International Growth Study. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. J Clin Endocrinol Metab. 2000; 85: 4212-8.

  24. Saenger P, Albertson-Wikland K, Conway GS. Recommendations for the diagnosis and management of Turner syndrome. J Clin Endocrinol Metab. 2001; 86: 3061-9.

  25. Van Pareren YK, de Muinck Keizer-Schrama SM, Stijen T. Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab. 2003; 88: 1119-25.

  26. Participants of the Scientific Weekend, Human Growth Hormone, Viena 10-11th October, 2003: Management of Turner’s syndrome. J Pediatr Endocrinol Metab. 2004; 17 Supl 2: 257-61.

  27. Vimalachandra D, Craig JC, Cowell C, Knight JF. Growth hormone for children with chronic renal failure. Cochrane Database Syst Rev. 2001; 4: CD003264.

  28. Obata K, Sakazume S, Yoshino A, Murakami N, Sakuta R. Effect of 5 years growth hormone treatment in patients with Prader-Willi syndrome. J Pediatr Endocrinol Metab. 2003; 16: 155-62.

  29. Hintz RL, Attie KM, Baptista J, Roche A. Effect of growth hormone treatment on adult height for children with idiopathic short stature. Genentech Collaborative Group. N Engl J Med. 1999; 340: 502-7.

  30. Wit JM, Rekes-Mombarg LT. Dutch Growth Hormone Advisory Group. Final height gain by GH therapy in children with idiopathic short stature is dose dependent. J Clin Endocrinol Metab. 2002; 87: 604-11.

  31. Ogata T, Fukami M. Clinical features in SHOX haploinsufficiency: diagnostic and therapeutic implications. Growth Genet Horm. 2004; 2: 17-23.

  32. Kofoed EM, Hwa V, Little B. Growth hormone insensitivity associated with STAT5b mutation. N Engl J Med. 2003; 349: 1139-47.

  33. Carel JC, Huet F, Chaussain JL. Treatment of growth hormone deficiency in very young children. Horm Res. 2003; 60 Supl 1: 10-7.

  34. Albertsson-Wikland K, Rosberg S, Karlberg J, Groth T. Analysis of 24-hour growth hormone profiles in healthy boys and girls of normal stature: relation to puberty. J Clin Endocrinol Metab. 1994; 78: 1195-201.

  35. Olivié MAA, Garcia-Mayor RV, Lestón DG. Serum insulin-like growth factor (IGF) binding protein-3 and IGF-1 levels during childhood and adolescence. A cross-sectional study. Pediatr Res. 1995; 38: 149-55.

  36. Juul A, Dalgaard P, Blum WF. Serum levels of insulin-like growth factor (IGF)-binding protein-1 (IGFBP-3) in healthy infants, children, and adolescents: the relation to IGF-1, IGF-2, IGFBP-1, IGFBP-2, age, sex, body mass index and pubertal maturation. J Clin Endocrinol Metab. 1995; 80: 2534-2.

  37. Clayton P, Cowell C. Safety issues in children and adolescents during growth hormone therapy. Growth Horm IGF Res. 2000; 10: 306-17.

  38. Ranke MB, Lindberg A, David AD. The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose. J Clin Endocrinol Metab. 2003; 88: 4748-53.

  39. Karlberg J, Kwan C, Gelander L, Albertsson-Wikland K. Pubertal growth assessment. Horm Res. 2003; 60 Supl 1: 27-35.

  40. Saenger P. Dose effects of growth hormone during puberty. Horm Res. 2003; 60 Supl 1: 52-7.

  41. Ranke MB, Martin DD, Lindberg A, on behalf of the KIGS International Board. Prediction model of total pubertal growth in idiopathic growth hormone deficiency: analysis of data from KIGS. Horm Res. 2003; 60 Supl1: 58-9.

  42. Papagianni M, Stanhope R. Should the dose of growth hormone be increased during the growth spurt of children with isolated growth hormone deficiency? J Pediatr Endocrinol Metab. 2003; 16: 1095-7.

  43. Schweizer J. Cortical bone density is normal in pre-pubertal children with growth hormone (GH) deficiency, but initially decreases during GH replacement due to early bone remodeling. J Clin Endocrinol Metab. 2003; 88: 5266-72.

  44. Amato G, Mazzioti G, Di Somma C. Recombinant growth hormone (GH) therapy in GH-deficient patients: a long-term controlled study on daily versus thrice weekly injection. J Clin Endocrinol Metab. 2000; 85: 178-85.

  45. De Zegher F, Albertsson-Wikland K, Wollmann HA. Growth hormone treatment of short children born small for gestational age: growth response with continuous and discontinuous regimens over 6 years. J Clin Endocrinol Metab. 2000; 85: 2816-21.

  46. Lee PA, Charnausek SD, Hokken-Koelega ACS, Czernichow P, on behalf of the International small for gestational age Advisory Board consensus development conference statement. Management of short children born small for gestational age. Pediatrics. 2003; 111: 1253-61.

  47. Vicens-Calvet E, Espadero RM, Carrascosa A. Longitudinal study of the pubertal growth spurt in children born small for gestational age without postnatal catch-up growth. J Clin Endocrinol Metab. 2002; 15: 381-8.

  48. Ranke MB, Lindberg A, Cowell CT, Alobertsson-Wikland K, Reiter EO, Wilton P, et al, on behalf of the KIGS International Board. Prediction of response to growth hormone treatment in short children born small for gestational age: Analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab. 2003; 88: 125-31.

  49. De Zegher F, Ong K, van Helvoirt M, Mohn A, Woods K, Dunger D. High-dose growth hormone (GH) treatment in non-GH deficient children born small for gestational age induces growth response related to pretreatment GH secretion and associated with a reversible decrease in insulin sensitivity. J Clin Endocrinol Metab. 2002; 87: 148-51.

  50. Participants of the Scientific Weekend, Human Growth Hormone, Viena 10-11th October, 2003. How effective and safe is growth hormone therapy in children born small for gestational age? J Pediatr Endocrinol Metab. 2004; 17 Supl 2: 263-6.

  51. Van Pareren Y, Mulder P, Houdijk M, Jansen M, Reeser M, Hokken-Koelega A. Effect of discontinuation of growth hormone treatment on risk factors for cardiovascular disease in adolescents born small for gestational age. J Clin Endocrinol Metab. 2003; 88: 347-53.

  52. Cohen P, Clemmons D, Rosenfeld R. Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res. 2000; 10: 297-305.

  53. Swerdlow A. Design and interpretation of studies of the risk cancer and other long-term morbidity and mortality after GH treatment. Growth Horm IGF Res. 2000; 10: 318-23.

  54. Powles T. Effect of human growth hormone in hemato-oncology patients receiving intensive chemotherapy. A double blind randomized, placebo-controlled study. Blood. 2003; 11: 388a.

  55. Gudmundsdottir A, Schlechte JA. Central hypothyroidism. Endocrinology. 2002; 12: 218-23.

  56. Rose SR, Manasco PK, Pearce S, Nisula BC. Hypothyroidism and deficiency of the nocturnal thyrotrophin surge in children with hypothalamic-pituitary disorders. J Clin Endocrinol Metab. 1990; 70: 1750-5.

  57. Lippe BM, van Herle AJ, LaFranchi SH, Uller RP, Lavin N, Kaplan SA. Reversible hypothyroidism in growth hormone-deficient children treated with human growth hormone. J Clin Endocrinol Metab. 1975; 40: 612-68.

  58. Municchi G, Malozowski S, Nisula BC, Cristiano A, Rose SR. Nocturnal thyrotropin surge in growth hormone-deficient children. J Pediatr. 1992; 121: 214-20.

  59. Jorgensen JO, Ovesen P, Juul A, Hansen TK, Skakkebaek NE, Christiansen JS. Impact of growth hormone administration on other hormonal axes. Horm Res. 1999; 51 Supl 3: 121-6.

  60. Chernausek SD. Managing the transition of adolescent with GH deficiency. J Endocrinol Invest. 2001; 24: 676-80.

  61. Quigley CA. The patient with growth hormone deficiency: issues in the transition from childhood to adulthood. Curr Opin Endocrinol Diabetes. 2003; 10: 277-89.

  62. Jennifer ME. Transition to the adult endocrine clinic: testing pituitary function–what tests and when? Growth Horm IGF Res. 2003; 13: 117-21.

  63. De Boer H, van der Veen EA. Why retest young adults with childhood-onset growth hormone deficiency? Growth Horm IGF Res. 2001; 11: 137-65.

  64. Hartman ML, Crowe BJ, Biller BM, Ho KK, Clemmons DR, Chipman JJ. Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? J Clin Endocrinol Metab. 2002; 87: 477-85.

  65. Maghinie M, Strigazzi C, Tinelli C. Growth hormone (GH) deficiency (GHD) of childhood onset: reassessment of GH status and evaluation of the predictive criteria for permanent GHD in young adults. J Clin Endocrinol Metab. 1999; 84: 1324-8.

  66. Clayton PE, Price DA, Shalet SM. Growth hormone state after completion of treatment with growth hormone. Arch Dis Child. 1987; 62: 222-8.

  67. Wacharasindhu S, Cotterill AM, Camacho-Hubner C, Besser GM, Savage MO. Normal growth hormone secretion in growth hormone insufficient children retested after completion of linear growth. Clin Endocrinol. 1996; 45: 553-6.

  68. Nicolson A, Toogood A, Rahim A, Shalet SM. Prevalence of severe growth hormone deficiency in adults who received growth hormone replacement in childhood. J Clin Endocrinol Metab. 1996; 44: 311-6.

  69. Shimon A. Growth hormone replacement for adult growth hormone deficiency. Expert Opin Pharmacother. 2003; 4: 1977-83.

  70. Rosenfeld RG, Nicodemus BC. The transition from adolescence to adult life: Physiology of the “transition” phase and its evolutionary basis. Horm Res. 2003; 60 Supl 1: 74-7.

  71. Leong GM, Johansson G. Growth hormone deficiency: Strategies and indications to continue growth hormone therapy in transition from adolescence to adult life. Horm Res. 2003; 60 Supl 1: 78-85.

  72. Fjellestad-Paulsen A, Simon D, Czernichow P, on behalf of the SGA Study Group. Short children born small for gestational age and treated with growth hormone for three years have an important catch-down five years after discontinuation of treatment. J Clin Endocrinol Metab. 2004; 89: 1234-9.




2020     |     www.medigraphic.com